Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer

Detalles Bibliográficos
Autores principales: Guan, Xiuwen, Ma, Fei, Li, Qiao, Chen, Shanshan, Fan, Ying, Wang, Jiayu, Luo, Yang, Zhang, Pin, Li, Qing, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025258/
https://www.ncbi.nlm.nih.gov/pubmed/36935426
http://dx.doi.org/10.1038/s41392-023-01322-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025258/
https://www.ncbi.nlm.nih.gov/pubmed/36935426
http://dx.doi.org/10.1038/s41392-023-01322-w

Ejemplares similares